Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to $2.7 million.

  • Serina Therapeutics' Accounts Payables rose 6112.09% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 6112.09%. This contributed to the annual value of $744000.0 for FY2024, which is 2827.59% up from last year.
  • As of Q3 2025, Serina Therapeutics' Accounts Payables stood at $2.7 million, which was up 6112.09% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Accounts Payables registered a high of $4.0 million during Q1 2024, and its lowest value of $580000.0 during Q4 2023.
  • Its 5-year average for Accounts Payables is $1.4 million, with a median of $1.2 million in 2025.
  • As far as peak fluctuations go, Serina Therapeutics' Accounts Payables skyrocketed by 21798.73% in 2024, and later crashed by 7039.62% in 2025.
  • Quarter analysis of 5 years shows Serina Therapeutics' Accounts Payables stood at $771000.0 in 2021, then soared by 34.11% to $1.0 million in 2022, then crashed by 43.91% to $580000.0 in 2023, then increased by 28.28% to $744000.0 in 2024, then skyrocketed by 267.07% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $1.7 million for Q2 2025, and $1.2 million during Q1 2025.